This document is a publication of a United States patent application (US20260083720A1) filed by Vyluma Inc. The application describes a topical formulation containing 0.01% atropine, which is claimed to safely and effectively reduce myopia progression in children. Notably, the application states this lower concentration was unexpectedly more effective than a 0.02% formulation and slowed progression compared to untreated subjects.

As this is a patent application, it does not impose immediate regulatory requirements or compliance deadlines on entities. However, it signals potential future market entry for a new myopia treatment. Companies involved in ophthalmic pharmaceuticals or medical devices should be aware of this development for competitive intelligence and potential licensing or partnership opportunities. The application was filed on October 6, 2023, and published on March 26, 2026.